Recent Finacing
Recent Raise
AgilVax develops xCT (SLC7A11)-targeted antibody therapeutics and a VLP vaccine (AX09), advancing preclinical-to-IND studies, ADC/radiopharmaceutical programs, and cGMP manufacturing for cancer indications.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Agilvax.
